Lenz Therapeutics Inc. announced that Lotus Pharmaceutical has submitted a New Drug Application (NDA) to the Ministry of Food and Drug Safety (MFDS) in South Korea for VIZZ, a treatment for presbyopia in adults. This submission is the first under the exclusive license and commercialization agreement signed in May 2025 between Lenz Therapeutics and Lotus Pharmaceutical, which covers South Korea and certain Southeast Asian countries. Under the agreement, Lenz Therapeutics is eligible to receive up to $125 million in regulatory and commercial milestone payments, as well as tiered, double-digit royalties on future net sales. Lotus Pharmaceutical holds exclusive rights for the development, manufacturing, registration, and commercialization of VIZZ in South Korea and several Southeast Asian countries.